ADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering

Phase III data suggest oral PCSK9 inhibitor enlicitide delivers substantial LDL-C lowering without compromising glycemic control. Phase III data suggest oral PCSK9 inhibitor enlicitide delivers substantial LDL-C lowering without compromising glycemic control. Enlicitide may address an important unmet need among patients who are unwilling or unable to use injectable therapies. Credit: Orawan Pattarawimonchai/Shutterstock.com. This year at the American Diabetes Association (ADA) Scientific Sessions, new Phase III data were presented evaluating the safety and efficacy of enlicitide, a late-stage investigational oral Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor. The analysis demonstrated significant reductions in Low-Density Lipoprotein Cholesterol (LDL-C) among participants with…

Source: Clinical Trials Arena